The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials
Open accessAbstract
Points• Adherence to prescribed treatment remains a critical component of clinical trials in tuberculosis (TB) treatment.Recent evidence indicates that adherence strongly influences the outcome of therapy; attention to its quantification and measures to assure its implementation should increase.• In the context of a World Health Organization (WHO) Technical Consultation on "Advances in Clinical Trial Design for Development of New TB Treatments," we reviewed the challenges related to adherence confronting the trials community.• We discuss the importance of adherence to therapy in TB clinical trials, consider several definitions and measures of adherence, comment on the standard provided by directly observed therapy (DOT), and briefly review evolving electronic methods for the assessment of adherence.• Adherence affects both the outcome of therapy and the risk of acquired drug resistance.Assessment of adherence should consider not only overall adherence but also the timing and intensity of nonadherence.• Appropriate methods for pooling and analyzing electronic data on adherence are needed.• Better methods are needed for linking information on adherence to individual pharmacokinetics and pharmacodynamics and to individual patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Treatment adherence is related to drug pharmacokinetics that causes a lower peak drug concentration than normal; in contrast, additional doses may result in a higher risk of toxicity than usual peak concentrations.30”
From The effects of acceptance and commitment therapy on psychosocial impact and adherence of multidrug-resistant tuberculosis patients (2022) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brożek, J., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw376 · Cited by 1,542
Self-citationFox, W., Ellard, G. A., & MITCHISON, D. A. (1999) · PubMed · Cited by 676
The Coronary Drug Project Research Group (1980) · New England Journal of Medicine · doi:10.1056/nejm198010303031804 · Cited by 659
Directly observed therapy for treating tuberculosis
Karumbi, J., & Garner, P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003343.pub4 · Cited by 646
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Gillespie, S. H., Crook, A. M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murray, S. R., Pappas, F., Phillips, P. P. J., & Nunn, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407426 · Cited by 644
The Effect of Directly Observed Therapy on the Rates of Drug Resistance and Relapse in Tuberculosis
Weis, S. E., Slocum, P. C., Blais, F. X., King, B., Nunn, M., Matney, G. B., Gomez, E., & FORESMAN, B. H. (1994) · New England Journal of Medicine · doi:10.1056/nejm199404283301702 · Cited by 588
Alipanah, N., Jarlsberg, L., Miller, C., Linh, N. N., Falzon, D., Jaramillo, E., & Nahid, P. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002595 · Cited by 503
Self-citationWhen Tuberculosis Treatment Fails: A Social Behavioral Account of Patient Adherence
Sumartojo, E. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/147.5.1311 · Cited by 463
Blaschke, T. F., Osterberg, L. G., Vrijens, B., & Urquhart, J. (2011) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011711-113247 · Cited by 420
Research works printed but not linked: 5
- NYC Bureau of Tuberculosis Control, 2008, Clinical Policies and Protocols, 66
- HR Stagg, 2018, How do tuberculosis patients really take their treatment?, A detailed quantitative approach, 22, S171
- S Huan, 2012, Operational feasibility of medication monitors in monitoring treatment adherence among patients, Chin J Antituberculosis, 34, 419
- Thomas B, Kumar V, Chiranjeevi M, Ramachandran G, Murugesan P, Khandelwale AS, et al. Evaluating the accuracy of 99DOTS, a cellphone-based strategy for monitoring TB treatment adherence [Abstract PS18-588-26]. In: 49th Union World Conference on Lung Health, 2018 Oct 26, The Hague, The Netherlands.
- World Health Organization, 2018, Report of the Technical Consultation on Advances in Clinical Trial Design for Development of New TB Treatments, Glion-sur-Montreux, Switzerland, 14–16 March 2018
Cited by
Sorted by citations
Items 101–102 of 102
Jones, M. B., Koram, K. A., Anto, F. R., Lauzardo, M., Restrepo, B. I., Lartey, M. S., Gbadamosi, H., & Kwara, A. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1755479
The bacterial pH gradient contributes to persistence in Mycobacterium tuberculosis
Eldesouky, H. E., Adams, K. N., Brache, J. K., Aguila, L. K. T., Garcia, M., Xing, E., Li, P., & Sherman, D. R. (2026) · mBio · doi:10.1128/mbio.01692-26
Metadata
- Authors
- Vernon, A., Fielding, K., Savic, R., Dodd, L., & Nahid, P.
- Affiliations
- Centers for Disease Control and Prevention (US)
- University of the Witwatersrand (ZA)
- National Institutes of Health (US)
- San Francisco General Hospital (US)
- Corresponding author
- Vernon, Andrew
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-12-10
- Volume
- 16
- Issue
- 12
- Pages
- e1002884
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC6903706
- OpenAlex
- W2994185183
- Cited by
- 104
- References
- 35
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 19 · 2023: 23 · 2022: 11 · 2021: 21 · 2020: 9
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Funders
- Centers for Disease Control and Prevention
- Medical Research Council (MR/R010161/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- tuberculosis, medication adherence, clinical trial design, explanatory trials, pragmatic trials, directly observed therapy, electronic adherence monitoring, drug resistance, pharmacokinetics/pharmacodynamics
- MeSH terms
- Clinical Trials as Topic, Humans, Research Design, Tuberculosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
